BridgeMD
Tests treatment safety and results for Autosomal Dominant Polycystic Kidney Disease
Official title ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ClinicalTrials.gov ID: NCT06902558
What this study is testing
What is ABBV-CLS-628?
ABBV-CLS-628 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for autosomal dominant polycystic kidney disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys. The purpose of this study is to assess the safety and efficacy of ABBV-CLS-628 for the treatment of ADPKD in adult participants.
- Phase 2: a mid-size study of how well it works
- Time commitment: about 15 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 55
You may be able to join if
- Autosomal Dominant Polycystic Kidney Disease (ADPKD) Class 1C, 1D, or 1E based on the Mayo Clinic Imaging Classification of ADPKD.
- Estimated glomerular filtration rate (eGFR) \>= 30 mL/min/1.73 m\^2 and \< 90 mL/min/1.73 m\^2, using the Chronic Kidney Disease Epidemiology...
You likely can't join if
- Current interventions to treat ADPKD such as non-approved medications or lifestyle modifications.
- Any exclusionary medical diseases, disorders, or conditions as described in the protocol.
The study team makes the final eligibility decision.
Where it's taking place
- Garden Grove, California, United States
- Huntington Park, California, United States
- Los Angeles, California, United States
- Orange, California, United States
- San Francisco, California, United States
- New Haven, Connecticut, United States
- Coral Gables, Florida, United States
- Fort Lauderdale, Florida, United States
- Inverness, Florida, United States
- Jacksonville, Florida, United States
- Miami, Florida, United States
- Sanford, Florida, United States
- Atlanta, Georgia, United States
- Boise, Idaho, United States
- Idaho Falls, Idaho, United States
- Chicago, Illinois, United States
- Iowa City, Iowa, United States
- Kansas City, Kansas, United States
- Boston, Massachusetts, United States
- Ann Arbor, Michigan, United States
+ 50 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 15 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 55 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Garden Grove, California, United States; Huntington Park, California, United States; Los Angeles, California, United States; Orange, California, United States; San Francisco, California, United States; New Haven, Connecticut, United States and 64 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.